<DOC>
	<DOCNO>NCT02793544</DOCNO>
	<brief_summary>This multi-center , single arm Phase II study hematopoietic cell transplantation ( HCT ) use human leukocyte antigen ( HLA ) -mismatched unrelated bone marrow transplantation donor post-transplantation cyclophosphamide ( PTCy ) , sirolimus mycophenolate mofetil ( MMF ) graft versus host disease ( GVHD ) prophylaxis patient hematologic malignancy .</brief_summary>
	<brief_title>HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Leukemia , Biphenotypic , Acute</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<mesh_term>Mesna</mesh_term>
	<criteria>1 . Age ≥ 15 year &lt; 71 year time signing informed consent form 2 . Partially HLAmismatched unrelated donor : HLA type perform high resolution ( allele level ) HLAA , B , C , DRB1 locus ; minimum match 4/8 HLAA , B , C , DRB1 require 3 . Product plan infusion bone marrow 4 . Disease disease status : 1 . Acute Leukemias T lymphoblastic lymphoma 1st subsequent complete remission ( CR ) : Acute lymphoblastic leukemia ( ALL ) /T lymphoblastic lymphoma ; acute myelogenous leukemia ( AML ) ; acute biphenotypic leukemia ( ABL ) ; acute undifferentiated leukemia ( AUL ) 2 . Myelodysplastic Syndrome ( MDS ) , fulfil follow criterion : Subjects de novo MDS previously Intermediate2 High risk disease determine International Prognostic Scoring System ( IPSS ) . Current Intermediate2 High risk disease requirement ; Subjects must &lt; 20 % bone marrow blast , assess within 60 day inform consent ; Subjects may receive prior therapy treatment MDS prior enrollment 3 . Chronic Lymphocytic Leukemia ( CLL ) CR RIC use ; CR partial response ( PR ) FIC use 4 . Chemotherapysensitive lymphoma status 1st CR 5 . Performance status : Karnofsky Lansky score ≥ 60 % ( Appendix A ) 6 . Adequate organ function define : 1 . Cardiac : leave ventricular ejection fraction ( LVEF ) rest ≥ 35 % ( RIC cohort ) LVEF rest ≥ 40 % ( FIC cohort ) , leave ventricular shorten fraction ( LVFS ) ≥ 25 % 2 . Pulmonary : diffusing capacity lung carbon monoxide ( DLCO ) , forced expiratory volume ( FEV1 ) , force vital capacity ( FVC ) ≥ 50 % predict pulmonary function test ( PFTs ) 3 . Hepatic : total bilirubin ≤ 2.5 mg/dL , alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) , alkaline phosphatase ( ALP ) &lt; 5 x upper limit ( ULN ) ( unless disease relate ) 4 . Renal : serum creatinine ( SCr ) within normal range age ( see table 2.3 ) . If SCr outside normal range age , creatinine clearance ( CrCl ) &gt; 40 mL/min/1.73m2 must obtain ( measure 24hour ( hr ) urine specimen nuclear glomerular filtration rate ( GFR ) , calculate GFR ( CockcroftGault formula age ≥ 18 year ; Original Schwartz estimate &lt; 18 year ) ) 7 . Subjects ≥ 18 year age must ability give informed consent accord applicable regulatory local institutional requirement . Legal guardian permission must obtain subject &lt; 18 year age . Pediatric subject include age appropriate discussion order obtain assent . 8 . Subjects documentation confirm HIV1 infection ( i.e . HIVpositive ) , hematologic malignancy meet eligibility requirement must : 1 . Receive RIC regimen ( i.e . Regimen A ) 2 . Be willing comply effective antiretroviral therapy ( ARV ) 3 . Have achieve sustain virologic response 12 week cessation hepatitis C antiviral treatment ( HIVpositive subject hepatitis C ) 1 . HLAmatched related 8/8 allele match ( HLAA , B , C , DRB1 ) unrelated donor available . This exclusion apply HIVpositive subject CCR5delta32 homozygous donor . 2 . Autologous HCT &lt; 3 month prior time signing informed consent form 3 . Females breastfeed pregnant 4 . HIVpositive subject : 1 . Acquired immunodeficiency syndrome ( AIDS ) relate syndrome symptom may pose excessive risk transplantationrelated morbidity determine Treatment Review Committee ( see Appendix D ) . 2 . Untreatable HIV infection due multidrug ARV resistance . Subjects detectable standard viral load &gt; 750 copies/mL evaluate HIV drug resistance test ( HIV1 genotype ) . The result include part ARV review ( described Appendix D ) . 3 . May currently prescribe ritonavir , cobacistat and/or zidovudine 5 . Current uncontrolled bacterial , viral fungal infection ( currently take medication evidence progression clinical symptom radiologic finding ) 6 . Prior allogeneic HCT 7 . History primary idiopathic myelofibrosis 8 . MDS subject may receive RIC must &lt; 50 year age time sign informed consent form 9 . Subjects may eligible inclusion Blood Marrow Transplant Clinical Trials Network ( BMT CTN ) 1101 protocol</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>